Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 2/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16731491 | 0.79 | AVPR1A (0.45) | AVPR1A | |
| SCHEMBL16404358 | 0.78 | GRM2 (0.46) | — | |
| SCHEMBL6926581 | 0.71 | IDO1 (0.45) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL17557419 | 0.70 | IDO1 (0.41) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL6927612 | 0.70 | IDO1 (0.42) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL16404361 | 0.69 | CA12 (0.34) | — | |
| SCHEMBL6927583 | 0.67 | GRM2 (0.65) | — | |
| SCHEMBL6926018 | 0.67 | IDO1 (0.44) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL17557418 | 0.66 | IDO1 (0.42) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL15236760 | 0.64 | GRM2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-9226930-B2 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRM2, GRM3, GRM1 | IDO1 995/4885TNKS 3229/4885TNKS2 2697/4885 |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | IDO1 1145/4885TNKS 3017/4885TNKS2 2437/4885 |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | IDO1 1150/4885TNKS 3258/4885TNKS2 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.